SCHEMBL19902589

SCHEMBL19902589

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1ccc(-n2cncn2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 5/20 0.58
SMYD3 Q9H7B4 1/20 0.57
ROCK2 O75116 3/20 0.44
PDCD1 Q15116 1/20 0.41
CD274 Q9NZQ7 1/20 0.41
RAB9A P51151 4/20 0.40
MAPT P10636 1/20 0.40
TAOK1 Q7L7X3 1/20 0.39
TAOK3 Q9H2K8 1/20 0.39
NPC1 O15118 2/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
DRD2 P14416 1/20 0.37
HTR2A P28223 1/20 0.37
DRD3 P35462 1/20 0.37
PRKAB2 O43741 1/20 0.37
PRKAG1 P54619 1/20 0.37
PRKAA2 P54646 1/20 0.37
PRKAA1 Q13131 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452899 0.88 ROCK2 (0.58) ROCK1SMYD3ROCK2PDCD1CD274
SCHEMBL19902714 0.83 ROCK1 (0.58) ROCK1ROCK2RAB9AMAPTTAOK1
SCHEMBL19902383 0.79 CYP1A2 (0.48) SMYD3ROCK2RAB9AMAPTNPC1
SCHEMBL19902605 0.78 CCNC (0.55) ROCK1SMYD3ROCK2RAB9ANPC1
SCHEMBL19902586 0.76 ROCK2 (0.45) ROCK1ROCK2RAB9ANPC1SMN1; SMN2
SCHEMBL19902349 0.76 MEN1 (0.44) ROCK1SMYD3ROCK2RAB9ANPC1
SCHEMBL19902577 0.76 NPC1 (0.44) ROCK1SMYD3ROCK2RAB9ANPC1
SCHEMBL19902492 0.76 TAOK1 (0.44) ROCK1SMYD3ROCK2RAB9ATAOK1
SCHEMBL19902627 0.76 PARP1 (0.54) ROCK2KMT2AMEN1DRD2HTR2A
SCHEMBL19902582 0.76 ROCK1 (0.47) ROCK1ROCK2RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 ROCK1 1/4885SMYD3 1799/4885ROCK2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.